Weight loss Novo Nordisk - Search News

News

Eli Lilly, Novo Nordisk and Weight Loss

Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic.

Barron's on MSN · 2d

Eli Lilly Stock Soars on Weight-Loss News. Why It’s Bad for Novo Nordisk.

Eli Lilly stock soared Thursday after the pharmaceutical giant said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to face off with Ozempic maker Novo Nordisk.

Investopedia on MSN · 1d

Novo Nordisk Stock Drops on Eli Lilly Oral Weight-Loss Drug Success, Downgrade

Key Takeways U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer's stock.

1d

Novo Nordisk: A Price Too Low To Ignore

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

2don MSN

How a New Weight-Loss Pill Could Transform Health

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

2don MSN

Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results